Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity

[Image: see text] Ibrutinib is a covalent BTK inhibitor that is approved for several indications in oncology. Ibrutinib possesses significant off-target activities toward many kinases, often leading to adverse events in patients. While there have been robust medicinal chemistry efforts leading to mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Toenjes, Sean T., Heydari, Bahar S., Albright, Samuel T., Hazin, Ramsey, Ortiz, Maria A., Piedrafita, F. Javier, Gustafson, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009787/
https://www.ncbi.nlm.nih.gov/pubmed/36923918
http://dx.doi.org/10.1021/acsmedchemlett.2c00523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009787/
https://www.ncbi.nlm.nih.gov/pubmed/36923918
http://dx.doi.org/10.1021/acsmedchemlett.2c00523

Ejemplares similares